By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



30 Worcester Road

Toronto  Ontario  M9W 5X2  Canada
Phone: 416-798-3001 Fax: 416-798-3007



Company News
IntelliPharmaCeutics Updates Status Of Tentative Approvals Of Generic Focalin XR 6/19/2015 7:23:36 AM
FDA Grants Fast Track Designation For IntelliPharmaCeutics Rexista Oxycodone XR Incorporating PODRAS Technology 5/26/2015 6:38:03 AM
IntelliPharmaCeutics Buys Property That Houses R&D & Office in Toronto, Ontario 5/26/2015 5:38:28 AM
IntelliPharmaCeutics Intends To Accelerate Its Rexista(TM) Oxycodone XR Development Program On The Basis Of Positive Feedback From The FDA 5/21/2015 10:26:01 AM
IntelliPharmaCeutics Reports Director Election Results 4/22/2015 2:01:18 PM
IntelliPharmaCeutics Announces First Quarter 2015 Results 4/15/2015 3:29:17 PM
IntelliPharmaCeutics Reports Positive Topline Data Results From A Series Of Phase I Clinical Trials Of Its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, And Files An IND For Rexista(TM) Oxycodone XR 3/30/2015 12:42:39 PM
IntelliPharmaCeutics Announces 2014 Year End Results With A 48% Reduction In Operating Loss 2/23/2015 7:55:51 AM
IntelliPharmaCeutics Reports The Signing Of An Exclusive Licensing And Manufacturing Agreement With TEVA Pharmaceuticals USA (TEVA) For An Extended Release Oral Drug Product Candidate 2/2/2015 7:54:49 AM
IntelliPharmaCeutics Notes Launch Of 5mg Strength Of Focalin XR(R) Generic By Teva Pharmaceutical Industries Limited (TEVA) 11/20/2014 10:33:07 AM